Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C
HIV Coinfection

Interventions

DRUG: TDF with a boosted protease inhibitor
DRUG: TAF with a boosted protease inhibitor
DRUG: TAF with a boosted protease inhibitor and LDV/SOF

Sponsor

University of Colorado, Denver